Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dental Pulp Mesenchymal Cells for Depression
NCT05127369Phase 2Unknown
- Sponsor
- CARsgen Therapeutics
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, randomised, double-blind trial of dental pulp mesenchymal cell injection in major depressive disorder (MDD) (2 arms), sponsored by CARsgen Therapeutics. Primary endpoint: Change in Montgomery Asperger Depression Scale Total Score at 8 weeks. Status: unknown.
02
Drugs
dental pulp mesenchymal cell injection
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05127369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127369.